S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

DISEASE CHARACTERISTICS: * Participant must have bone metastasis from multiple myeloma, solid tumors, or other malignancy for which intravenous bisphosphonate has clinical indications in the treatment of metastatic bone disease * Treatment with osteoclast inhibition is clinically indicated * Must be planning to receive zoledronic acid\* within the next 30 days NOTE: \*Osteoclast inhibition therapy will continue thereafter as clinically indicated. * No prior diagnosis of osteonecrosis of the jaw * Patients previously treated with osteoclast inhibition therapy are eligible, provided the following criteria apply: * Prior osteoclast inhibition for low bone mass (osteoporosis or osteopenia): * Patients may have previously received at most 3 doses of osteoclast-inhibiting therapy with denosumab, IV ibandronate, pamidronate, or zoledronic acid for low bone mass (osteopenia or osteoporosis) within 3 years prior to registration * Prior oral bisphosphonate therapy at osteoporosis or osteopenia dosing at any time prior to registration is allowed * Prior exposures to other medications used to treat low bone mass at osteoporosis or osteopenia dosing are permitted * Prior osteoclast inhibition for metastatic bone disease (tumor involving bone): * Patients may have previously received osteoclast-inhibiting therapy with denosumab, ibandronate (oral or IV cancer dosing), pamidronate, or zoledronic acid to treat metastatic bone disease within 180 days prior to registrat…